


IMV Revenue
Biotechnology Research • Halifax, Nova Scotia, Canada • 11-20 Employees
IMV revenue & valuation
| Annual revenue | $212,000 |
| Revenue per employee | $12,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $678,400 |
| Total funding | $25,000,000 |
Key Contacts at IMV
Altino Ono
Owner
Truong Quoc Toan
Assistant Of Director
Glenn Ayre
Owner
Company overview
| Headquarters | 130 Eileen Stubbs Ave, Dartmouth, Nova Scotia B3B, CA |
| Phone number | +17273030750 |
| Website | |
| SIC | 873 |
| Keywords | Cancer, Oncology, Immunotherapy, Breast Cancer, Bladder Cancer, Immuno-Oncology, Ovarian Cancer, Dpx Platform, Dlbcl, Solid Cancer |
| Founded | 2000 |
| Employees | 11-20 |
| Socials |
IMV Email Formats
IMV uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 42.1% |
{first name}@company.com | john@company.com | 25.3% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 14.8% |
{first name}{last name}@company.com | johndoe@company.com | 10.2% |
{last name}@company.com | doe@company.com | 7.6% |
About IMV
IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company’s immune-educating platform: the DPX® technology. Through a differentiated mechanism of action, the DPX® platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. IMV’s lead candidate, maveropepimut-S (MVP-S), delivers antigenic peptides of survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers. MVP-S treatment has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. MVP-S is currently being evaluated in clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma (DLBCL) as well as ovarian, bladder and breast cancers. For more information, please connect at: www.imv-inc.com
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
IMV has 17 employees across 9 departments.
Departments
Number of employees
IMV Tech Stack
Discover the technologies and tools that power IMV's digital infrastructure, from frameworks to analytics platforms.
CDN
JavaScript libraries
Databases
Miscellaneous
Programming languages
Miscellaneous
Caching
Blogs
JavaScript libraries
JavaScript libraries
JavaScript libraries
WordPress themes
Frequently asked questions
4.8
40,000 users



